[144] Cytosorbents Corp. SEC Filing

Rhea-AI Filing Summary

Cytosorbents Corp. (CTSO) filed a Form 144 reporting a proposed sale of 10,548 common shares through Fidelity Brokerage Services with an approximate sale date of 08/19/2025. The filing shows the shares were acquired on 08/14/2025 by restricted stock vesting from the issuer as compensation. The aggregate market value of the planned sale is listed as $11,447.74 and the company reports 62,761,805 shares outstanding. No other sales in the past three months are reported.

Positive

• The filing clearly discloses acquisition method as restricted stock vesting, linking the sale to compensation rather than external purchase.
• All required fields for the planned sale are provided: number of shares, aggregate market value, approximate sale date, broker name, and shares outstanding.

Negative

• An insider plans to sell vested shares, which is a disposition by an insider (though the amount appears immaterial relative to total outstanding shares).
• Several filer and issuer identifying fields (CIK, filer name, issuer name/address, submission contact details) are not presented in the provided content.

Insights

Financial Analyst

TL;DR: Routine insider sell of vested compensation shares; size is immaterial relative to outstanding shares.

The Form 144 documents a planned sale of 10,548 common shares valued at $11,447.74, representing roughly 0.017% of the 62.76 million shares outstanding. The shares were acquired via restricted stock vesting and are being sold through Fidelity Brokerage Services with an approximate sale date of 08/19/2025. This appears to be a compensation-related disposition rather than a large-scale insider liquidation, and no other sales in the prior three months are reported.

Corporate Compliance / Securities Attorney

TL;DR: Filing meets Rule 144 disclosure for a compensatory vesting sale; no material compliance red flags visible in the notice.

The notice identifies the nature of acquisition (restricted stock vesting), the broker (Fidelity Brokerage Services), the number of shares, aggregate market value, and an approximate sale date, consistent with Rule 144 requirements. The signer affirms no undisclosed material adverse information. Absent additional context (e.g., a trading plan date), the filing reads as a routine compliant disclosure of a scheduled sale of vested compensation shares.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	10548	11447.74	62761805	08/19/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/14/2025	Restricted Stock Vesting	Issuer			10548	08/14/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Cytosorbents (CTSO) report in the Form 144?

The Form 144 reports a proposed sale of 10,548 common shares through Fidelity Brokerage Services with an approximate sale date of 08/19/2025 and aggregate market value of $11,447.74.

How were the shares acquired that are being sold?

The shares were acquired on 08/14/2025 by restricted stock vesting from the issuer and paid as compensation on the same date.

How large is the planned sale relative to total shares outstanding?

The company reports 62,761,805 shares outstanding; the proposed sale of 10,548 shares is roughly 0.017% of outstanding shares.

Were there other sales by the same person in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months.

Which broker is handling the proposed sale?

The broker listed is Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield RI 02917.